The influence of histone acetylation on DCM seems to involve the recruitment of transcriptional regulators, since the treatment with an inhibitor of bromodomain-containing protein-4 (BRD4), apabetalone, decreased the risk of major adverse cardiovascular events and the frequency of hospitalizations after recent acute coronary syndrome in DM2 patients [68,69]. Here, BRD4 is linked to acute coronary syndrome.